EBOS lifts full-year profit on best-ever sales result
Make us a preferred source
Make us a preferred source on Google
The news: EBOS Group reported a rise in full-year statutory net profit driven by its best-ever sales result, as annual revenue passed NZD13 billion ($11.86 billion) for the first time.
The numbers: The medical product wholesaler and distributor reported statutory net profit after tax of NZD271.5 million, up 7.2% on FY23. Revenue grew 7.8% year over year to NZD13.2 billion as EBITDA lifted 6.5% to NZD605.6 million.
The Christchurch-based company declared a final dividend of 61.5 NZ cents per share, bringing total dividends to 118.5 NZ cents, up 7.7% compared to a year earlier.
The group guided underlying EBITDA in FY25 of between NZD575 million and NZD600 million.
The context: EBOS said its record sales revenue reflected growth in its community pharmacy and institutional healthcare divisions. The company noted the full-year result was driven by continued organic growth as well as a number of strategic investments during the year.
The company increased its shareholding Southeast Asian medical device distributor Transmedic, completed the acquisition of Superior Pet Food, and finalised four small bolt-on acquisitions in the medical technology and medical consumables businesses across Australia, New Zealand and South East Asia.
What they said: "The group’s diversification is a key strength as we navigate challenging domestic economic conditions, and we have a strong pipeline of opportunities ahead of us as we continue to expand our operations outside New Zealand and Australia," said EBOS CEO John Cullity.
The source: ASX announcement
